Posted by Michael Wonder on 02 Sep 2022
FDA still skeptical of ALS drug ahead of high stakes meeting
3 September 2022 - The U.S. FDA has posted another negative review of a closely watched drug for the deadly neurodegenerative disease ALS.
Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig’s disease, even as they prepare to give its drugmaker a rare second opportunity to make a public case for the treatment.
